<?xml version="1.0"?>
<rss version="2.0">
	<channel>
		<title>News (category : Scientific - Pipeline - Regulatory).</title>
		<link>http://www.lifescience-online.com/</link>
		<description>News Feed Powered by Lifescience-online.com</description>
		<language>en-us</language>
		<pubDate>Wed, 07 Jan 2009 14:15:38 +0100</pubDate>
		<lastBuildDate>Wed, 07 Jan 2009 14:15:38 +0100</lastBuildDate>
		<category>News</category>		

		<image>
			<title>Lifescience-online</title>
			<url>http://rss.lifescience-online.com/images/logo.gif</url>
			<link>http://www.lifescience-online.com/</link>
			<width></width>
			<height></height>
			<description>Lifescience-online</description>
		</image>

		<item>
			<title>DOR BioPharma Obtains Fast Track Designation for DOR201 in the Prevention of Acute Radiation Enteritis</title>
			<link>http://www.lifescience-online.com/DOR_BioPharma_Obtains_Fast_Track_Designation_for_D,13631.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/5/2.gif' /></div><dl><dt><b>Area</b> :</dt><dd>Oncology</dd><br /><dt><b>Category</b> :</dt><dd>Scientific - Pipeline - Regulatory</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/dor_biopharma,5548.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>DOR BIOPHARMA INC</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/TIME-RELEASE_ORAL_BECLOMETHASONE_DIPROPIONATE,24367.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>TIME-RELEASE ORAL BECLOMETHASONE DIPROPIONATE</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Tue, 06 Jan 2009 12:09:45 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>Advaxis, Inc. Phase II Clinical Trial HOLD Lifted</title>
			<link>http://www.lifescience-online.com/Advaxis__Inc__Phase_II_Clinical_Trial_HOLD_Lifted,13640.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/5/1.gif' /></div><dl><dt><b>Area</b> :</dt><dd>Oncology</dd><br /><dt><b>Category</b> :</dt><dd>Scientific - Pipeline - Regulatory</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/advaxis,4888.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>Advaxis Inc</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/LOVAXIN_C,20354.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>LOVAXIN C</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Mon, 05 Jan 2009 23:00:00 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>DOR BioPharma Receives SPA Clearance From the FDA to Begin Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD</title>
			<link>http://www.lifescience-online.com/DOR_BioPharma_Receives_SPA_Clearance_From_the_FDA_,13610.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/5/1.gif' /></div><dl><dt><b>Area</b> :</dt><dd>Immunomodulation</dd><br /><dt><b>Category</b> :</dt><dd>Scientific - Pipeline - Regulatory</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/dor_biopharma,5548.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>DOR BIOPHARMA INC</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/ORAL_BECLOMETHASONE_DIPROPIONATE,2257.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>ORAL BECLOMETHASONE DIPROPIONATE</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Mon, 05 Jan 2009 13:52:29 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>Idera Pharmaceuticals Announces Publication of Studies on Chemistry of Novel Antagonists for Toll-like Receptors 7 and 9</title>
			<link>http://www.lifescience-online.com/Idera_Pharmaceuticals_Announces_Publication_of_Stu,13609.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/5/0.gif' /></div><dl><dt><b>Category</b> :</dt><dd>Scientific - Pipeline - Regulatory</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/idera_pharmaceuticals,5827.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>Idera Pharmaceuticals Inc</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/TLR-7,8,9_AGONISTS,22903.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>TLR-7,8,9 AGONISTS</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Mon, 05 Jan 2009 13:41:49 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>BioDelivery Sciences Closes $6 Million Transaction with Meda</title>
			<link>http://www.lifescience-online.com/BioDelivery_Sciences_Closes__6_Million_Transaction,13608.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/5/0.gif' /></div><dl><dt><b>Category</b> :</dt><dd>Scientific - Pipeline - Regulatory</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/biodelivery_sciences_international,379.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>BIODELIVERY SCIENCES INTERNATIONAL INC</u></font></a><br /><a href='http://www.lifescience-online.com/meda_ab,9528.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>MEDA AB</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/TRANSMUCOSAL_(BEMA)_FENTANYL,24181.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>TRANSMUCOSAL (BEMA) FENTANYL</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Mon, 05 Jan 2009 12:12:53 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>Prism Pharmaceuticals, Inc. Receives FDA Approval of NEXTERONE(R) for Life-Threatening Ventricular Fibrillation and Ventricular Tachycardia</title>
			<link>http://www.lifescience-online.com/Prism_Pharmaceuticals__Inc__Receives_FDA_Approval_,13613.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/5/3.gif' /></div><dl><dt><b>Area</b> :</dt><dd>Cardiovascular</dd><br /><dt><b>Category</b> :</dt><dd>Scientific - Pipeline - Regulatory</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/prism_pharmaceuticals,9104.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>PRISM PHARMACEUTICALS INC</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/AMIODARONE_HYDROCHLORIDE,10585.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>AMIODARONE HYDROCHLORIDE</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Sun, 04 Jan 2009 23:00:00 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>Genta Incorporated (GNTA) Summarizes Phase 2 Activity and Receives Orphan Drug Designation in Gastric Cancer for Tesetaxel, a Leading Oral Taxane in Clinical Development</title>
			<link>http://www.lifescience-online.com/Genta_Incorporated__GNTA__Summarizes_Phase_2_Activ,13619.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/5/1.gif' /></div><dl><dt><b>Area</b> :</dt><dd>Oncology</dd><br /><dt><b>Category</b> :</dt><dd>Scientific - Pipeline - Regulatory</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/genta,5732.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>Genta Inc</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/DJ-927,2422.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>DJ-927</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Sun, 04 Jan 2009 23:00:00 GMT</pubDate>
			<category>News</category>
		</item>

		<item>
			<title>Cubist Pharmaceuticals, the Developer of CUBICIN, Announces Submission of 2 INDs Targeting Serious Infections Caused by MDR Gram-negative Pathogens and by Clostridium difficile</title>
			<link>http://www.lifescience-online.com/Cubist_Pharmaceuticals__the_Developer_of_CUBICIN__,13620.html?portalPage=Lifescience+Today.News</link>
			<description><![CDATA[
<div valign='top' style='position:absolute;'><img align='right' src='http://static.lifescience-online.com/commonimages/news/5/0.gif' /></div><dl><dt><b>Area</b> :</dt><dd>Anti-Infective</dd><br /><dt><b>Category</b> :</dt><dd>Scientific - Pipeline - Regulatory</dd><br /><dt><b>Related companies</b> :</dt><dd><a href='http://www.lifescience-online.com/cubist_pharmaceuticals,510.html?portalPage=Business.Key+Players'><font color='#003366'><u color='#003366'>CUBIST PHARMACEUTICALS INC</u></font></a></dd><br /><dt><b>Related drugs</b> :</dt><dd><a href='http://www.lifescience-online.com/CB-183315,24413.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>CB-183315</u></font></a><br /><a href='http://www.lifescience-online.com/CB-182804,24414.html?portalPage=Drugs'><font color='#003366'><u color='#003366'>CB-182804</u></font></a></dd><br /><br /></dl>
]]></description>
			<pubDate>Sun, 04 Jan 2009 23:00:00 GMT</pubDate>
			<category>News</category>
		</item>

	</channel>
</rss>